Coronary Artery Disease Clinical Trial
Official title:
Feasibility and Effectiveness of a Real-time Heart Team Approach in Complex Coronary Artery Disease
This study is aimed to evaluate the clinical outcomes, efficiency and feasibility of the real-time heart team approach and the conventional heart team approach.
Status | Not yet recruiting |
Enrollment | 490 |
Est. completion date | December 31, 2024 |
Est. primary completion date | September 30, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 100 Years |
Eligibility | Inclusion Criteria: 1. Significant stenosis in the left main or left main equivalent with or without stenosis in one of the other vessels[Significant stenosis is defined as: 1) a diameter stenosis of at least 50% reduction in luminal diameter by visual assessment or 2) any total occlusion (no age limitation and no exclusion of unfavorable anatomic features); Left main equivalent disease is defined as significant stenosis of the ostium of the left anterior descending and the ostium of the left circumflex.] 2. At least 1 significant stenosis in all 3 major epicardial territories supplying viable myocardium; 3. Other conditions that the interventional cardiologist considers necessary to discuss with cardiac surgeons due to technical and risk considerations. Exclusion Criteria: 1. Less than 18 years of age; 2. Previous history of PCI or CABG; 3. Admitted for AMI, ECG and biomarker detection indicated acute stage; 4. Patients with severe heart valvular disease, major vascular disease, and giant ventricular aneurysm require surgical treatment; 5. Combined with AF or severe arrhythmia; 6. Other patients admitted to hospital due to emergency circumstances who are not suitable to wait for elective revascularization; 7. Rejection or exclusion of a revascularization mode (PCI or CABG); 8. Refuse to participate in the study. |
Country | Name | City | State |
---|---|---|---|
China | China National Center for Cardiovascular Diseases | Beijing | Beijing |
Lead Sponsor | Collaborator |
---|---|
China National Center for Cardiovascular Diseases |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | 1-year major adverse cardiovascular and cerebrovascular events | a composite of all-cause death, myocardial infarction, stroke, repeated revascularization, ischemic symptoms with hospital admission. | At 1 year after the coronary angiography | |
Secondary | time interval between the completion of coronary angiography and the final treatment | time interval is considered as a key secondary outcome | through study completion, an average of 1 year | |
Secondary | the appropriateness rate of heart team decisions | assessment of the heart team dicision appropriateness according to Appropriateness Use Criteria and guidelines | through study completion, an average of 1 year | |
Secondary | heart team decision distribution | assessment of the heart team dicision distribution, such as the rate of CABG, PCI, and medical treatment | through study completion, an average of 1 year | |
Secondary | working load of organizing heart team meetings | to assess the work load of arganising heart team meetings by NASA-TLX | through study completion, an average of 1 year | |
Secondary | success rate of heart team organization | to assess the successful-connection with cardiac surgeons during or after the coronary angiography | through study completion, an average of 1 year | |
Secondary | time consuming of heart team discussions | to assess the time consuming of heart team organization and discussion during or after the coronary angiography | through study completion, an average of 1 year | |
Secondary | length of stay | to assess length of stay (LOS) before the final treatment, and the totol LOS in hospital | through study completion, an average of 1 year | |
Secondary | total cost | to assess the total cost in hospital for the initial hospitalization and rehospitalization | through study completion, an average of 3 year | |
Secondary | time interval of each diagnosis and treatment procedures | to assess the time consuming of the angiography to heart team meeting time and heart team meeting to final treatment time | through study completion, an average of 1 year | |
Secondary | individual clinical adverse events | including all-cause death, cardiac death, myocardial infarction, stroke, revascularization of target vessels or transplanted vessels, revascularization for any reason, be admitted to hospital with angina again, readmission for cardiac reasons and readmission for any reason | At 1 year after the coronary angiography |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06030596 -
SPECT Myocardial Blood Flow Quantification for Diagnosis of Ischemic Heart Disease Determined by Fraction Flow Reserve
|
||
Completed |
NCT04080700 -
Korean Prospective Registry for Evaluating the Safety and Efficacy of Distal Radial Approach (KODRA)
|
||
Recruiting |
NCT03810599 -
Patient-reported Outcomes in the Bergen Early Cardiac Rehabilitation Study
|
N/A | |
Recruiting |
NCT06002932 -
Comparison of PROVISIONal 1-stent Strategy With DEB Versus Planned 2-stent Strategy in Coronary Bifurcation Lesions.
|
N/A | |
Not yet recruiting |
NCT06032572 -
Evaluation of the Safety and Effectiveness of the VRS100 System in PCI (ESSENCE)
|
N/A | |
Recruiting |
NCT04242134 -
Drug-coating Balloon Angioplasties for True Coronary Bifurcation Lesions
|
N/A | |
Recruiting |
NCT05308719 -
Nasal Oxygen Therapy After Cardiac Surgery
|
N/A | |
Completed |
NCT04556994 -
Phase 1 Cardiac Rehabilitation With and Without Lower Limb Paddling Effects in Post CABG Patients.
|
N/A | |
Recruiting |
NCT05846893 -
Drug-Coated Balloon vs. Drug-Eluting Stent for Clinical Outcomes in Patients With Large Coronary Artery Disease
|
N/A | |
Recruiting |
NCT06027788 -
CTSN Embolic Protection Trial
|
N/A | |
Recruiting |
NCT05023629 -
STunning After Balloon Occlusion
|
N/A | |
Completed |
NCT04941560 -
Assessing the Association Between Multi-dimension Facial Characteristics and Coronary Artery Diseases
|
||
Completed |
NCT04006288 -
Switching From DAPT to Dual Pathway Inhibition With Low-dose Rivaroxaban in Adjunct to Aspirin in Patients With Coronary Artery Disease
|
Phase 4 | |
Completed |
NCT01860274 -
Meshed Vein Graft Patency Trial - VEST
|
N/A | |
Recruiting |
NCT06174090 -
The Effect of Video Education on Pain, Anxiety and Knowledge Levels of Coronary Bypass Graft Surgery Patients
|
N/A | |
Terminated |
NCT03959072 -
Cardiac Cath Lab Staff Radiation Exposure
|
||
Completed |
NCT03968809 -
Role of Cardioflux in Predicting Coronary Artery Disease (CAD) Outcomes
|
||
Recruiting |
NCT04566497 -
Assessment of Adverse Outcome in Asymptomatic Patients With Prior Coronary Revascularization Who Have a Systematic Stress Testing Strategy Or a Non-testing Strategy During Long-term Follow-up.
|
N/A | |
Recruiting |
NCT05065073 -
Iso-Osmolar vs. Low-Osmolar Contrast Agents for Optical Coherence Tomography
|
Phase 4 | |
Completed |
NCT05096442 -
Compare the Safety and Efficacy of Genoss® DCB and SeQuent® Please NEO in Korean Patients With Coronary De Novo Lesions
|
N/A |